Endogenex Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
Endogenex General Information
Description
Developer of a medical device system designed to improve metabolic function in individuals with diabetes by resetting metabolic signalling in the small intestine. The company's device delivers controlled, non-thermal pulsed electric fields through an endoscopic procedure to promote duodenal tissue regeneration, enabling patients with type 2 diabetes to better manage blood glucose and support metabolic health.
Contact Information
Website
www.endogenex.comCorporate Office
- 13755 1st Avenue North
- Suite 100
- Plymouth, MN 55441
- United States
Corporate Office
- 13755 1st Avenue North
- Suite 100
- Plymouth, MN 55441
- United States
Endogenex Timeline
Endogenex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 5. Later Stage VC (Series C) | 25-Mar-2026 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series B1) | 17-Oct-2023 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 01-Aug-2022 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A2) | 20-Apr-2021 | $12M | $24.9M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 05-Dec-2018 | $12.9M | $12.9M | Completed | Startup |
Endogenex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B-1 | ||||||||
| Series A-2 | 13,692,251 | $0.000100 | $0.07 | $0.88 | $0.88 | 1x | $0.88 | 6.88% |
| Series A | 19,102,460 | $0.000100 | $0.05 | $0.67 | $0.67 | 1x | $0.67 | 9.6% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Endogenex Comparisons
Industry
Financing
Details
Endogenex Competitors (2)
One of Endogenex’s 2 competitors is DiogenX, a Venture Capital-Backed company based in Marseille, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DiogenX | Venture Capital-Backed | Marseille, France | ||||
| Fractyl Health | Formerly VC-backed | Burlington, MA |
Endogenex Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Endogenex Patents
Endogenex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260102193-A1 | Devices, systems, and methods for pulsed electric field treatment of tissue | Pending | 14-Oct-2024 | ||
| WO-2026085052-A1 | Devices, systems, and methods for pulsed electric field treatment of tissue | Pending | 14-Oct-2024 | ||
| WO-2025264907-A1 | Ferritin directed duodenal mucosal recellurization | Pending | 19-Jun-2024 | ||
| AU-2025260095-A1 | Devices, systems, and methods for pulsed electric field treatment of tissue | Pending | 25-Apr-2024 | ||
| AU-2025260576-A1 | Devices, systems, and methods for pulsed electric field treatment of tissue | Pending | 25-Apr-2024 |
Endogenex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Endogenex Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arboretum Ventures | Venture Capital | Minority | ||
| Hatteras Venture Partners | Venture Capital | Minority | ||
| Lumira Ventures | Venture Capital | Minority | ||
| Orlando Health Ventures | Corporate Venture Capital | Minority | ||
| Southeast Minnesota Capital Fund | Venture Capital | Minority |
Endogenex FAQs
-
When was Endogenex founded?
Endogenex was founded in 2017.
-
Where is Endogenex headquartered?
Endogenex is headquartered in Plymouth, MN.
-
What is the size of Endogenex?
Endogenex has 29 total employees.
-
What industry is Endogenex in?
Endogenex’s primary industry is Therapeutic Devices.
-
Is Endogenex a private or public company?
Endogenex is a Private company.
-
What is Endogenex’s current revenue?
The current revenue for Endogenex is .
-
How much funding has Endogenex raised over time?
Endogenex has raised $190M.
-
Who are Endogenex’s investors?
Arboretum Ventures, Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, and Southeast Minnesota Capital Fund are 5 of 9 investors who have invested in Endogenex.
-
Who are Endogenex’s competitors?
DiogenX and Fractyl Health are competitors of Endogenex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
